![]() Process for preparing derivatives of n-(4-indolylpiperidinoalkyl)benzimidazolone or their acid salts
专利摘要:
The method of obtaining derivatives of N- 公开号:SU1088665A3 申请号:SU823396888 申请日:1982-02-24 公开日:1984-04-23 发明作者:Фритер Курт;Фукс Виктор;Оливер Джеймс 申请人:Берингер Ингельгейм Лтд (Фирма); IPC主号:
专利说明:
Subsequent hydrogenation is carried out at temperatures around η normal or higher pressure. Suitable noble metals of the catalyst are palladium or platinum. The compounds of the general formula (1) are basic and thereby form 1 SILICON additive salts with inorganic or organic acids. Physiologically tolerable acid addition salts mo.gut be formed, for example, halogen hydrogenous acids, preferably hydrochloric acid or hydrobromic acid, nitric acid, sulfuric acid, o-phosphoric, tartaric, citric, maleic, fumaric, propionic, butyric constant, acetic, succinic , methanesulfonic. benzenesulfonic, p-toluenesulfonic acids, etc. Example 1. Hydrochloride Y- {3- 4- (2-methyl-3-indolyl) piperidino but 2-pr opil j benzimyd az ol he. A mixture consisting of 1.06 g of 2-methyl- 3- (1, 2,5,6-t ester agidropyridyl-4-indole, 1.05 g of N- (3-chloro-propyl) - benzimidazolone, 0.42 g of sodium bicarbonate, 20 ml of dimethylformamide and 20 ml of tetrahydrofuran, while stirring, are heated to 100 ° C for 18 hours. Then the reaction mixture is poured into a mixture of 200 g of ice and 100 ml of concentrated ammonia, forming a precipitate. the dock is filtered and recrystallized from ethanol. v This gives 1.2 g (62% of the theoretical) of a product of formula IV having a melting point of 215 ° C, at which,,, 1.5 g of the product is dissolved in 100 ml of acetic acid acid and for 24 hours together with 0.8 g of palladium (5% on. coal), shake at 20 ° C in a hydrogen atmosphere and under a pressure of 5 at. Then the catalyst is filtered and the filtrate is poured into a mixture of ice and ammonia, and K) 1 separates the free base. The precipitate is filtered, dried, dissolved in ethanol and converted into hydrochloride by the addition of Ester Hydrochloric Acid. 1.05 g (70% of theory) of the title compound is obtained with a melting point of 264-269 ° G. Example 2 H- {4- 4- (3-Indoles-Piperidino-Butyl-Benzimidazolone. Mixture consisting of 3 g of 4- (3-indyl) -piperidine, 4 g of 1- (4 -chlorobutyl-3-yzopropenyl-benzimidazolone, 1.3 g of sodium bicarbonate, 30 ml of dimethylformamide and 30 ml of tetragl 1drofuran are heated under reflux for 16 hours. Then the reaction mixture is poured into a mixture of ice and ammonia, extracted with ethyl acetate and the resulting solution is passed through water , dried and evaporated in vacuo to dryness. The residue is dissolved in ether, ethereal ethereal acid is added and a precipitate is formed (и il, dried and dissolved in 100 ml of ethanol. The resulting solution is cooled, 16 ml of concentrated sulfuric acid are added with thorough stirring and the mixture is left to stand for 2 hours at 20 C. The mixture is then poured into a mixture of ice and ammonia, the resulting precipitate is filtered and recrystallized from ethanol, 3.2 g (55% of the theoretical) of the title compound with a melting point of 196 ° C are obtained. The following compounds are obtained in analogy with Examples I and 2. 1. N-3-t4 - (- 1-Mustil-3-indolyl) -piperidine-propyl and -benzimidazolone with a melting point. Yield 62%. Y H- {3-C4- (3-Indo-lyl) -piperidino-3-propyl-benzimidazolone hydrochloride with a melting point of 240 s. Yield 58%. III. Hydrochloride (5-methoxy-3-indolshI) -piperidino-2-pprppil I-benzimidazolone with melting point. Yield 71%. Similar to that described in example 2 of. 4- (Z-cycloyl) -piperidine. IV.Y- {3- 4- (3-indole-1) -piperidium Hoi-npommj-N-isopropenyl-benzimidazolone with a melting point of 68 C. 42%. V .. H- {3- 4- (1-isopropyl-3-indolyl) -piperidino-propyl-benzimidazolone hydrochloride with melting point. Yield 66%. .VI. H- {2-C4- (3-indolsh1) -piperidineO; - .Etyl,} | -Benzimidazolone with a melting point. Yield 61%. VII. N- {3- 4- (3-ira Olsh1) -1 spheridino-3-propyl-methylbenzimidazolone hydrochloride with a melting point of 140 C. Yield, 70%. yill N-f3-t4- (l-propyl-3-indolyl) -piperidino-propyl-benzimidazolone with a melting point of 103 s. 74 h. IX.N- {3 - (; 4- (2-methyl-5-chlorop-3-indolyl) -piperidino-J-propyl) -ben zimidazolone with a melting point of 124 ° C. . Output 56%. X.N-f5-f4- (3-indolyl) -piperidino-lpj-benzimidazolone pentane with a melting point of 137-140 ° C. Yield 49%. XI. (3-Indolyl) -shheridino1-hexyl-benzim11dazolone with a melting point of 127-130 ° C. Yield 51%. A pharmacological study of new compounds has shown that eXTByiDT has two biological mechanisms: first, compounds stabilize mast cells and thus prevent the release of carrier substances, which take place as a result of an antigen reaction with an antibody or with other stimulating substances; secondly, the compounds have anti-histamine properties, they prevent the action of histamine, the main causative agent of human allergy. The first property was detected by mast cell stabilization studies, the second - by antihistamine action, and both properties are confirmed by the experience in determining passive cutaneous anaphylaxis (PKA) С A. The PKA experiment in rats. To achieve reproducible skin reactions in areas with diameters of 10–15 mm, unsensitized rats are given diluted egg albumin antiserum, 0.1 mp: this diluted anti-serum is injected intracutaneously into male rats weighing 150–160 g on each side of the shaved back, namely, to antigenic irritation. The compounds under study are dissolved in water, mixed with 0.5 ml of a solution of 5 mg of egg albumin and 2%; Evans blue and 1 ml / kg of this mixture are intravenously injected into animals after 24 h after passive sensitization. For the study of oral activity, the test compounds are suspended in a solution of acacia rubber, which in an amount of 1 ml / kg is given to animals with a stomach umbrella. After 20-30 minutes after oral administration, the test compounds cause antigenic irritation by giving 0.015 mg of egg albumin in 0.5 ml of a 2% Evans blue solution. After 15 minutes after antigenic irritation, 3 µg O are injected intradermally to induce a strong antihistamine effect. 1 ml of histamine in physiological saline solution. 30 minutes after the antigenic irritation, the rats are killed by C02. An incision is made along the spinal column, the skin is reclined, and the diameter of the blue-colored areas (mm) is measured. The average area of each spot (in mm) is determined and the average total area for the group of treated rats is calculated from the data obtained. The average area (in mm of the untreated control group is taken as 100% and the dose of the test compounds is determined, causing a 50% decrease in the painted area of the untreated control group (). The results are listed in the table. Known compound. The new compounds of general formula 1 have a more pronounced antiallergic activity B. B. Reduced area from blue skin of rats caused by histamine 1 Uzh rats weighing 150-160 g are divided into two groups. Rats of both groups are removed back hair. Untreated control the group was given orally 10 ml / kg of a normal physiological physiological solution of common salt in a 1% acacia rubber solution. The exposed: experience was also given orally 10 ml / kg of the studied dinen suspended in a 1% solution of actium rubber. , all animals are given intravenously 0.5 ml of a 2% Evans blue solution in normal physiological saline solution.After 20 minutes after giving the test compound or control solution on both sides of the shaved skin of the back of the rats, a solution of 3 μg diphosphate is injected intradermally and histamine in normal physiological saline solution. 15 minutes after the injection of histamine, the rats are sacrificed, all the rats are cut with CO using a CO. The skin is carefully separated along the spinal column. The back skin is reclined and the diameter of the spots dyed in blue is measured. For each blue spot, the area is calculated (the average area for the control and experimental groups is calculated. The average area of the control group is taken as 100% and the dose of test compounds is determined by linear regression, which causes a 50% reduction in the colored area of the control group. B. Inhibition of the peritoneal degranulation of mast cells DTK in rats passively sensitized with the help of the egg-albumin antiserum or by induction of a copolymer of N-methyl-homoanisylamine and formaldehyde Male rats weighing 150-160 g under Group 1 - nonspecific control of DHA (3 rats) Group TT - positive control of DTC (5 rats). Groups III, IV, V positive DTC after giving the test compound (5 rats, respectively). Rats of group 1 intrabranchically give 3 ml of normal rat serum. Rats of groups II-V also intraperitoneally give 3 ml of antiserum, causing 60-80% higher degranulation compared with normal rat serum. After 18-24 hours, the corresponding test compound is given, namely, for intravenous dacha, immediately, for intraperitoneal dacha, 5 minutes and for oral dacha, 20 minutes before antigenic irritation caused by 0.5 mg / kg twice crystallized egg albumin in O, 005% physiological saline solution. 15 minutes after the induction of irritation, the rats are killed by COj. If dp induction of mast cell degranulation used a copolymer of N-methylhomoanisylamine and formaldehyde, then group 1 is given 3 mp of solution. Hank with a pH value of 7.2-7.4. The positive control group and those groups that were given the test compound, were given intraperitoneally 20 µg / kg of the indicated compound in 3 ml of Hank's solution, having a pH value of 7.2-7.4. These rats were also killed by C02 after 5 min after intravital injection. To determine the size of mast cell degranulation in untreated and treated groups of rats, mesentery microtome sections are made, which are analyzed in a manner similar to that of Fügner. Results are calculated as percent inhibition of degranulation as follows. Experience-negative Perm. control of the positive-negative negative control role In the experiments described, the activity of benzimidazolone hydrochloride (4-indolyl) piperidino-Jpropyl j (4) and the known known compound oxatomide are investigated. The results of the experiments are summarized in the table. Oksatomid 8.3 Compound II1,6 Negate. 8.1 3.0-6.4 8.7 9 108866510 Experimental results confirm Compounds of general formula 1 or the double advantage of a new compound with an acid has antiallergini over the known: it has a remarkable efficiency and, therefore, significant stabilizing agents that are suitable for the treatment of 1 allergic non-bacterial cells along with good levels of 5, such as allergic antihistamine properties and in pyastma, rhinitis, conjunctivitis, senna times more active is the known compound fever, allergies to food prooxatomide products and others.
权利要求:
Claims (1) [1] A method of obtaining derivatives of I- (4-indolylpiperidinoalkyl benzimidazolone of the general formula O where R 1t R ^ .hRj have the indicated meanings, are reacted with a compound of the general formula where HZ and η have the indicated meanings; X is bromine or iodine, and the obtained product has the general formula SU (and , 1088665 where is hydrogen, chlorine or methoxy; R 2 is hydrogen, Cy-Cj is alkyl; R 3 is hydrogen, methyl; R4 is hydrogen, methyl, C ^ alkenyl, n = 2,3,4,5 or 6, or their salts with acids, wherein the compound is of the general formula where Rjp R ^, R ^, R 4 and n have the indicated values, or they are isolated in a free * form, or in the form of a salt with an acid, if the piperidine nucleus contains only simple bonds, or is hydrogenated with hydrogen in the presence of a noble metal, if the piperidine nucleus has a double bond, and then the target product is isolated.
类似技术:
公开号 | 公开日 | 专利标题 SU1088665A3|1984-04-23|Process for preparing derivatives of n-|benzimidazolone or their acid salts KR900004693B1|1990-07-02|4,5,6 - substituted - n - | -2- pyrimidinamins their preparation and composition of matter SU1340589A3|1987-09-23|Method of producing 2-|-4-amino-6,7-dimethoxy quinolines or hydrochlorides thereof SU969164A3|1982-10-23|Process for producing derivatives of phthalimidine or their salts US4215123A|1980-07-29|Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives EP0655440A2|1995-05-31|1-Aminoethylindoles CS223977B2|1983-11-25|Method of preparation of the chinazoline derivatives IE53274B1|1988-09-28|Chemical compounds derived from cyclobutene CH616674A5|1980-04-15| EA007225B1|2006-08-25|Derivatives of n-[phenyl|methyl]benzamide and application of same in therapeutics JP2006509014A|2006-03-16|Modulator of melanocortin receptor US4048182A|1977-09-13|Derivatives of imidazo [4,5-b]pyridines JPH07116156B2|1995-12-13|New derivatives of decahydroquinoline, their production method and drug TW438746B|2001-06-07|New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions PT85607B|1990-05-31|PROCESS FOR THE PREPARATION OF ANTI-ALLERGIC AND ANTI-INFLAMMATORY DIHYDROPYRIDINE AGENTS DE2239648A1|1973-02-22|POLYCYCLIC COMPOUNDS US4243666A|1981-01-06|4-Amino-2-piperidino-quinazolines SU1574177A3|1990-06-23|Method of obtaining derivatives of 4,5-dihydrooxazoles 4,5-substituted andro stendioneor their pharmaceutically acceptable salts US4522943A|1985-06-11|Chemical compounds JP3158638B2|2001-04-23|Novel aminophenol derivatives and their pharmaceutical uses EP0007399A1|1980-02-06|Indolylalkyl amines, pharmaceutical preparations containing them and process for their manufacture US8067422B2|2011-11-29|Crystal form of phenylamino pyrimidine derivatives US4503051A|1985-03-05|Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use HU196998B|1989-02-28|Process for producing basically substituted pyridine derivatives and pharmaceuticals comprising same US4180577A|1979-12-25|Furo[2, 3d]pyrimidine derivatives and anti-ulcer containing the same
同族专利:
公开号 | 公开日 AR228475A1|1983-03-15| NZ199822A|1985-01-31| PL235187A1|1984-03-26| EP0058975B1|1984-12-12| NO820583L|1982-08-26| ES8306142A1|1983-05-01| FI71558B|1986-10-10| ZA821196B|1983-10-26| FI71558C|1987-01-19| NO157296B|1987-11-16| JPH0318637B2|1991-03-13| ES517988A0|1984-01-01| KR830009086A|1983-12-17| IE52562B1|1987-12-09| PT74481B|1984-10-09| CA1191137A|1985-07-30| JPS57156484A|1982-09-27| EP0058975A1|1982-09-01| AT10742T|1984-12-15| GR74778B|1984-07-12| IE820401L|1982-08-25| DK151017B|1987-10-12| DK79882A|1982-08-26| YU42758B|1988-12-31| IL65097D0|1982-04-30| YU41082A|1985-03-20| ES8401961A1|1984-01-01| PH17889A|1985-01-21| UA7228A1|1995-06-30| NO157296C|1988-02-24| ES509871A0|1983-05-01| PL135472B1|1985-10-31| US4359468A|1982-11-16| DK151017C|1988-06-13| DD202562A5|1983-09-21| FI820594L|1982-08-26| HU187652B|1986-02-28| KR890000008B1|1989-03-02| GB2093455B|1984-06-13| GB2093455A|1982-09-02| DE3261497D1|1985-01-24| AU8078382A|1982-09-02| AU543948B2|1985-05-09| CS227343B2|1984-04-16| PT74481A|1982-03-01|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 BE794333A|1972-01-20|1973-07-19|Wyeth John & Brother Ltd|NITROGEN THERAPEUTIC HETEROCYCLIC COMPOUNDS| US3954764A|1973-03-30|1976-05-04|Hoffmann-La Roche Inc.|Dibenzo [b,f]thiepins bearing piperazinyl substitution| DE2322470A1|1973-05-04|1974-11-21|Boehringer Sohn Ingelheim|NEW INDOLYL-PIPERIDINO- BUTYROPHENONE AND METHOD FOR THEIR PRODUCTION| US4147786A|1976-02-02|1979-04-03|Ciba-Geigy Corporation|1-Indolylalkyl-3-or 4-trimethyleneurido-piperidines| ZA76475B|1975-03-10|1977-08-31|Ciba Geigy Ag|Indolyalkylpiperidines| FR2469411B1|1979-11-15|1982-11-19|Science Union & Cie| US4254127A|1980-04-03|1981-03-03|Janssen Pharmaceutica, N.V.|1,3-Dihydro-1-[alkyl]-2H-benzimidazol-2-one derivatives|US4548939A|1984-10-01|1985-10-22|Janssen Pharmaceutica N. V.|1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones| IE58370B1|1985-04-10|1993-09-08|Lundbeck & Co As H|Indole derivatives| US4742057A|1985-12-05|1988-05-03|Fujisawa Pharmaceutical Co., Ltd.|Antiallergic thiazole compounds| FR2613222B1|1987-04-03|1991-06-14|Guigon Nadine|COMPOSITION FOR LOCAL SKIN CARE, ESPECIALLY SCALP| DK733788A|1988-01-14|1989-07-15|Fujisawa Pharmaceutical Co|INDOLYL PIPERIDE INGREDIENTS AND PROCEDURES FOR PREPARING THEREOF| US5238945A|1989-04-11|1993-08-24|H. Lundbeck A/S|Method of treating psychoses| GB8908085D0|1989-04-11|1989-05-24|Lundbeck & Co As H|New therapeutic use| FR2658823B1|1990-02-27|1992-04-30|Adir|NOVEL AMINOMETHYLPIPERIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.| TW203049B|1990-04-13|1993-04-01|Yamanouchi Pharma Co Ltd| DE4414113A1|1994-04-22|1995-10-26|Merck Patent Gmbh|3-indolylpiperidines| AU3162695A|1994-08-03|1996-03-04|Asta Medica Aktiengesellschaft|Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects| US5521196A|1994-10-05|1996-05-28|Eli Lilly And Company|5-HT1F agonists for the treatment of migraine| US5521197A|1994-12-01|1996-05-28|Eli Lilly And Company|3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists| HU9800417A3|1995-03-20|2001-04-28|Lilly Co Eli|5-substituted-3--indoles and 5-substituted-3--1h-indoles, their use as new 5-ht agonists, pharmaceutical compositions containing these compounds| GB9825413D0|1998-11-19|1999-01-13|Lilly Co Eli|Pharmaceutical compounds| GB9903784D0|1999-02-18|1999-04-14|Lilly Co Eli|Pharmaceutical compounds| AU2003297597A1|2002-11-26|2004-06-18|Isis Pharmaceuticals, Inc.|Benzimidazoles and analogs thereof as antibacterials| AT531706T|2005-04-30|2011-11-15|Boehringer Ingelheim Int|NEW PIPERIDINE-SUBSTITUTED INDOLE AND ITS USE AS CCR-3 MODULATORS| JP2009515833A|2005-10-24|2009-04-16|ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ|3-piperidin-4-yl-indole ORL-1 receptor modulator| US8462477B2|2010-09-13|2013-06-11|Analog Devices, Inc.|Junction field effect transistor for voltage protection|
法律状态:
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US06/237,966|US4359468A|1981-02-25|1981-02-25|Antiallergic N-[4--piperidino-alkyl]-benzimidazolones| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|